Oticon Reveal. Following previously reported results showing 17% organic growth in its external hearing aid sales , Demant has released a fuller third-quarter (Q3) update pointing to a broader market rebound. The parent company of Oticon estimates US commercial hearing aid unit sales grew 8% year over year in Q3, following flat sales in Q2....
Continue reading at Hearing Tracker
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a market performance update with no implications for clinical practice.
A confirmed US market rebound after a downturn signals improved consumer demand, which may affect clinic revenue forecasts and inventory planning for hearing aid dispensers.
- 01Demant reported 17% organic growth in external hearing aid sales for Q3 2026.
- 02The growth signals a rebound in the US commercial hearing aid market following a prior downturn.
- 03The data comes from Demant's own quarterly business update, not an independent market report.
- 04Oticon is Demant's primary hearing aid brand in the US market.
Demant reported 17% organic growth in external hearing aid sales in Q3 2026.
press releasepartially supportedThe US commercial hearing aid market is rebounding in Q3 2026.
press releasepartially supported
